Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Psychopathology often begins and manifests, sometimes differently than in adults, in childhood and adolescence.
Assessment of children and adolescents requires developmentally-sensitive adjustments to diagnostic criteria.
Co-morbidities and symptoms from other disorders require consideration and sometimes targeted treatment interventions.
Despite the resilience of children and adolescents, treatments are necessary and appropriate to minimize the effects of psychopathology on the child's development.
Treatment planning for children and adolescents requires attention to configuring the environment to match the child's needs and existing skills, as well as consideration of biological and psychological therapies.
Children and adolescents bring diverse genetic, temperamental, perceptual, and sociological backgrounds to the environments in which they are raised. The unique constellations of these background variables match, some better and some worse, to fluctuating environmental pressures that are often outside of the control of the young person. Sometimes significant biological and/or environmental factors can stress the fit between the child and their surroundings, thereby increasing vulnerability to expressions of psychopathology. Childhood and adolescence may alter the expression of psychopathology described in adults, but young people can suffer as much as adults from psychiatric illness. Symptoms can emerge in children, particularly those who face intense stress, loss of a caregiver, chronic illness, or a personal or family history of psychiatric disorders.
Psychopathology often becomes detected as a child faces new developmental challenges. For example, children watch and emulate their caregivers as they ambulate, speak, play with others, and separate from parents to attend school. As the child faces each of these developmental hurdles, the developmental demands may exceed the child's abilities and increase the child's vulnerability for developing psychopathology. Different anxiety disorders are more prevalent at different ages; for example, separation anxiety more commonly emerges early in childhood (when the child transitions from home to school, or to a different school, or community), while obsessive-compulsive disorder (OCD) more commonly occurs later in childhood or during adolescence. Similarly, mood disorders are diagnosed more commonly during adolescence, as the challenge to fit in among peers may prove too difficult, while loneliness and isolation increase the risk of depression ( Tables 69-1 and 69-2 ).
Psychiatric Disorder | Prevalence Past 6 Months (%) |
---|---|
Any psychiatric disorder | 20.9 |
Anxiety disorders (includes generalized anxiety, separation anxiety, acute stress disorder, post-traumatic stress disorder, obsessive-compulsive disorder) | 13 |
Disruptive behavior disorders (includes attention-deficit/hyperactivity disorder, conduct disorder, oppositional defiant disorder) | 10.3 |
Mood disorders (includes depression, dysthymia, bipolar disorder) | 6.2 |
Substance abuse (includes abuse or dependence with any substance, including alcohol, marijuana, opiates, stimulants) | 2.0 |
Autism spectrum disorders (includes previous autism, Asperger's, PDD NOS) | <1% |
Disorder | Primary Symptom(s) |
---|---|
Intellectual disability | Decreased intellectual function and impairments in adaptive function (e.g., self-care, independence) |
Learning disorders | Achievement in reading, writing, math is below that expected based on intelligence |
Motor skills disorders | Impairments in motor coordination that affect daily living |
Communication disorders | Communication difficulties including expressing self, stuttering, reception of language, articulation |
Autism spectrum disorder | Impairments in social interaction and communication, and restricted interests |
Pica | Eating of non-nutritive substances |
Rumination disorder | Repeated regurgitation, re-chewing of food after normal feeding accomplished |
Avoidant/restrictive intake disorder | Eating disturbance which is based on sensory characteristics, worries about aversive events that leads to failure of nutritional needs to be met |
Tourette's disorder | Multiple motor tics and one or more vocal tics |
Persistent tic disorder | Motor or vocal tics |
Provisional tic disorder | Single or multiple motor and/or vocal tics that for less than 1 year |
Encopresis | Repeated passage of feces in inappropriate places monthly after reaching age 4 years |
Enuresis | Repeated voiding of urine twice weekly while asleep or causing distress or impairing function after reaching the age of continence |
Selective mutism | Persistent failure to speak in specific social situations where speaking expected, yet speaking in other situations |
Reactive attachment disorder | Markedly disturbed, inappropriate social relatedness before age 5 and associated with pathological care |
Stereotypic movement disorder | Driven, non-functional motor behaviors; may be self-harming |
A number of instruments are available to screen for the presence of psychopathology in children and adolescents ( Table 69-3 ). Commonly employed general instruments include the Pediatric Symptom Checklist, now available in multiple languages. This and other general and specific screening tools are available online at www.schoolpsychiatry.org .
General screening |
|
Anxiety symptoms |
|
ADHD symptoms |
|
Bipolar disorder/mania symptoms |
|
Depressive symptoms |
|
Obsessive-compulsive symptoms |
|
Psychosis |
|
Treatments continue to evolve, and psychosocial interventions increasingly are examined to clarify which components benefit and match to certain types of symptoms and to certain types of patients. Child psychiatry has experienced proliferation of medication treatment but special considerations are required due to children's unique metabolism, possible long-term consequences, and unusual reactions ( Box 69-1 ).
The use of psychotropic medications should follow a careful evaluation of the child and the family, including psychiatric, medical, and social considerations. Children who manifest transient symptoms related to an adjustment to medical illnesses or to losses should be considered for non-pharmacological treatment; pharmacological care should be reserved for refractory cases.
Pharmacotherapy should be considered as part of a comprehensive treatment plan that includes individual and family psychotherapy, educational and behavioral interventions, and careful medical management; it should not be presented as an alternative to these other interventions.
If a patient has a psychiatric disorder that may respond to psychotropic medications, the clinician should decide which psychotropic medication to use, and take into consideration the age of the child and the severity and nature of the symptomatic picture. Diagnosis and target symptoms should be defined before initiating pharmacotherapy.
The family and the child should be familiarized with the risks and benefits of this intervention, the availability of alternative treatments, the possible adverse effects, the potential for interaction with other medications, the realization of possible unforeseeable adverse events, and the prognosis with and without treatment. Providing patients with choices in treatments, including medications, may improve adherence to treatments. Permission to use medications should be obtained from the custodial parent or the patient's legal guardian. Standard use of antipsychotics in children and adolescents who are in the custody of the state may require a legal hearing; however, antipsychotics can be used in these patients in emergency situations.
Ongoing pharmacological assessment is necessary. When a medication is thought to be either ineffective or inappropriate to the current clinical situation, these agents should be tapered and discontinued under careful clinical observation. Appropriate alternative interventions should be reviewed with the family and then initiated.
The Food and Drug Administration (FDA) approves the use of medications in specified clinical situations. However, the FDA allows practitioners to use medications in clinical situations not included in the official labeling. That is, practitioners may use a medication for clinical situations other than the “approved” use or the use of medications in age groups not formally studied. Often, medical advances are made with use of drugs in conditions that are not as yet included on the package insert.
Previously the law of parsimony dictated a single cause for each symptom complex; this led to the use of large doses of individual agents for a given disorder, which can often result in intolerable adverse effects. In contrast, the use of combined pharmacotherapy has permitted more targeted treatment and greater efficacy, often achieved with lower doses and fewer adverse effects.
The diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders , ed 5 (DSM-5) require developmentally-sensitive adjustments to detect symptoms in patients at different ages.
When unremitting anxiety impairs the child across multiple domains, anxiety disorders should be considered. Anxiety problems often manifest in children as somatic complaints (such as headaches, stomachaches, and nervous twitches of unknown physiological nature). Further inquiry of the child or caregivers may reveal multiple fears or incapacitating worries. Often the child has a parent with an anxiety disorder. Childhood anxiety disorders are relatively common and may persist into adult life.
In separation anxiety, the predominant disturbance is a developmentally-inappropriate excessive anxiety on separation from familiar surroundings. A certain level of separation anxiety is an expected and healthy part of normal development that occurs in all children to varying degrees between infancy and age 6. Healthy separation anxiety is typically seen around 8 to 10 months of age, when an infant becomes anxious when meeting strangers (stranger anxiety). Children also may become mildly anxious around 18 to 24 months of age, when they are increasingly exploring their world but wanting to return to their caregiver frequently for security. In contrast, approximately 4% of children will experience separation anxiety disorder at some point with separation worries that are excessive and that overwhelm the child for even brief separations (such as leaving to go to school, going to sleep, or staying behind at home when a parent runs an errand). The child's fears usually appear to be irrational (such as a fear that the parent may suddenly die or become ill). People with separation anxiety disorder often go to great extremes to avoid being apart from their home or caregivers. They may protest against leaving a parent's side, refuse to play with friends, or complain about physical illness at the time of separating. When separation occurs or is even anticipated, the child may experience severe anxiety to the point of panic. It may develop during the preschool age, but more commonly appears in elementary-school-age children.
Environmental modifications are often important in the management of separation anxiety. Planned efforts to minimize the magnitude of separations (e.g., having the child transition between familiar adults [such as preferred school staff], constructing check-in notes from parents provided at various points during the preschool or school day, providing planned distracting or attractive activities as the child makes the transition) may all decrease separation fears.
Psychotherapy interventions, matched to the developmental level of the child, are often helpful. For younger children, identifying fears (that something may happen to their parent or to them, or to other adults or children) may provide clarity about the nature of the specific fear so that desensitization or successive approximations can be used to diminish anxiety. For example, for young children unable to sleep in their own rooms, sleeping on the floor, in the hall, or with a light or sibling nearby may prove viable once the child's particular distress becomes clear. Reinforcement for efforts toward sleeping alone is often needed to sustain the child's effort. Similarly, assessment of evidence that supports or negates fears, and steps to combat these fears (from relaxation techniques to keeping transitional objects, sometimes imbued with “special powers” to provide the child with strength or special skills) can replace the child's existing anxiety response. Sometimes a parent of the child with separation anxiety may similarly feel anxious around separations, so mindfulness about parent efforts and responses for separations may illuminate needs for reassurance and de-escalating acts for parents to decrease the cascade of anxiety that surrounds separations.
Antidepressants and benzodiazepines are frequently used together to enable children to both separate and tolerate separations. Selective serotonin reuptake inhibitors (SSRIs) are often initiated, while benzodiazepines are simultaneously provided for several weeks until the medication exerts significant effects. Low doses of clonazepam or lorazepam may be helpful and enable the child to separate and to acclimate to the parent-absent environment. In addition, some patients require evening doses of benzodiazepines initially to counter overwhelming anxiety as they anticipate separations at bedtime or the next day.
Obsessive-compulsive disorder (OCD) is among the best studied of the juvenile anxiety conditions. OCD often develops early in life; nearly one-quarter of males with obsessions report the onset of their symptoms before age 10 years, and cases of the disorder have been described as early as age 3. However, 40% of patients with OCD in childhood may remit by early adulthood. OCD is characterized by persistent ideas or impulses (obsessions) that are intrusive and senseless (e.g., thoughts of having caused violence, becoming contaminated, or severely doubting oneself) that may lead to persistent repetitive, purposeful behaviors (compulsions) (e.g., handwashing, counting, checking, or touching in order to neutralize the obsessive worries). Within the medical setting, this disorder is often associated with an exaggerated, persistent, and impairing obsession with an organ, disease process, or treatment. This disorder has been estimated to affect 1%–2% of the adult population; it has been shown to be familial and associated with Tourette's syndrome (TS) and attention-deficit/hyperactivity disorder (ADHD). OCD is most effectively treated with cognitive-behavioral treatment (CBT) or an SSRI, with combined CBT + SSRI treatment yielding the best outcomes. In addition, patients who are partial responders to an SSRI alone can benefit from augmentation with CBT.
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) have also been associated with OCD/tics. Plasma exchange, intravenous (IV) immunoglobulin, and penicillin have been used to treat OCD/tics associated with PANDAS. These treatments appear to be effective only for those patients (less than 10%) whose OCD/tics were associated with streptococcal infections.
A variety of therapies have been beneficial in the management of OCD. CBT, both with individuals and with groups of children having OCD, have proven efficacious, including “personifying” the obsessions (e.g., “Germy”), and identifying steps to “boss back Germy,” to recognize how much time the child plays with “Germy” instead of with peers (to make the obsessions more dystonic). Practicing compulsions differently to make them more uncomfortable and providing more appropriate “competing” responses to replace existing compulsions have been useful.
Pharmacotherapy with SSRI antidepressants remains the cornerstone of pharmacological treatments for OCD. Studies suggest that children with OCD respond in a fashion similar to adults, and may require doses up to four times the normal doses used to treat depression (i.e., 80 mg of fluoxetine instead of 20 mg daily). The SSRI antidepressants are Food and Drug Administration (FDA)-approved for OCD in the pediatric population (e.g., sertraline [Zoloft, initiated at 12.5 to 25 mg daily and titrated to 50 to 200 mg daily], fluvoxamine [Luvox, a more sedating drug that is initiated at 25 mg at bedtime and increased to 25 to 150 mg twice per day], and fluoxetine [Prozac, initiated at 5 to 10 mg and increased to 60 mg/day]).When SSRIs cannot be tolerated, or the patient is refractory to multiple SSRIs, the tricyclic antidepressant (TCA) clomipramine (Anafranil) has also been efficacious for pediatric OCD. A variety of additional pharmacotherapy strategies have been employed to augment SSRIs in severely impaired adolescents with OCD, including: atypical antipsychotics, such as aripiprazole, the amyotrophic lateral sclerosis (ALS) medication riluzole (although concerns about pancreatitis persist), emantine, and D-cycloserine. Despite these medication treatments, augmentation of CBT appears to be particularly efficacious.
Generalized anxiety disorder (GAD) of childhood is more frequently seen in boys than in girls. Similar to GAD in the adult patient, the essential feature is excessive worry and fear that is not focused on a specific situation or object and is not seen as a result of psychosocial stressors. Children may manifest an exaggerated or unrealistic response to the comments or criticisms of others. Less commonly, some children and adolescents experience panic attacks.
Patient education about the chronic nature of GAD and the fluctuating course of symptoms often associated with the emergence or decrease in stressors may provide reassurance to patients and decrease general stress levels. Psychotherapeutic support, using relaxation, deep breathing, and progressive muscle relaxation, may help children counter escalations of anxiety. Cognitive-behavioral techniques for appraising situations more completely and logically, and for accessing other input from others or evaluating all the evidence (e.g., the likelihood of a terrorist attack in a rural county), may enable children to control anxiety with cognitive skills.
Treatment of GAD in children is similar to the treatment of GAD in adults; SSRIs, benzodiazepines, TCAs, and beta-blockers appear to be effective. Buspirone, a non-benzodiazepine anxiolytic without anticonvulsant, sedative, or muscle-relaxant properties, may provide some benefit alone or by using it in combination with an SSRI. The effective daily buspirone dose is estimated to range from 0.3 to 0.6 mg/kg.
Acute stress disorder develops within days of a traumatic event and is manifest by anxiety, dissociative symptoms, persistent re-experiencing of the trauma, and avoidance of stimuli that raise recollections of the trauma. This disorder is likely to be observed in pediatric patients or their parents after acute injuries. The severity, duration, and proximity to the trauma are factors that influence the development of acute stress disorder, and approximately 20%–50% are reported after interpersonal traumatic events, like an assault or a mass shooting. In addition to the nature (e.g., burns, self-injurious behaviors, or abuse) and extent of the injuries, pre-existing psychiatric illness increases the risk of acute stress disorder.
If the stressful symptoms surrounding the trauma last beyond 1 month, the diagnosis changes to post-traumatic stress disorder (PTSD). PTSD may occur following a traumatic event that continues to haunt a person months later, beyond the “acute” reaction to a trauma. Children, like adults, may experience nightmares months to years after a traumatic event, as well as flashbacks or distressing recollections sometimes suppressed successfully for years. Sometimes patients will not have symptoms immediately following the traumatic event, but months or years later. Events resembling a past trauma may re-kindle the trauma, culminating in anxiety symptoms, or sometimes a person will experience PTSD when reaching a developmental point related to the trauma. For example, when children reach high school or college, have their own children, or experience the loss of someone, their distress may emerge as the trauma is re-experienced from a different role (e.g., older sibling or parent instead of child). While acute stress disorder and PTSD are not genetic disorders, vulnerabilities to anxiety reactions do have genetic components; in addition, some individuals live in more dangerous or chaotic environments, as do their children, so that PTSD may occur more commonly in some families. Approximately 8.7% of Americans have been reported to experience PTSD by the age of 75 years, although susceptibility to traumatic events increases one's risk of developing PTSD.
Efforts to help children separate themselves from the traumatic event and from the victim role, are helpful. Environmental changes to reduce further risks for the child often require interventions by adults to create safety for the child. Cognitive-behavioral techniques to help the child resist traumatic recollections, and to counter recurrent distressing thoughts, to de-escalate anxiety, and to distinguish time or setting variables that surrounded the event to diminish generalization of fears can allay symptoms. Anticipatory planning with family members, if nightmares or flashbacks occur, can diminish re-traumatization during the child's recollection of past events.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here